TGF-β/Smad3 pathway enhances the cardio-protection of S1R/SIPR1 in in vitro ischemia-reperfusion myocardial cell model

TINGFANG YANG1, XIANFENG ZHANG2, CUIMEI MA3 and YAN CHEN1

1Department of Pediatrics, Jining No. 1 People's Hospital, Jining, Shandong 272011; 2Department of Psychiatry, Jining Mental Health Hospital/Daizhuang Hospital of Shandong, Jining, Shandong 272051; 3Department of Pediatrics, Affiliated Hospital of Jining Medical University, Jining, Shandong 272000, P.R. China

Received February 6, 2017; Accepted August 16, 2017

DOI: 10.3892/etm.2018.6192

Abstract. Ischemia-reperfusion (IR) injury is usually associated with a high risk of cardiomyocyte death in patients with acute myocardial infarction. Sphingosine 1-phosphate (S1P) and transforming growth factor (TGF)-β are thought to be involved in the protection of cardiomyocyte and heart function following IR-induced injury. However, the possible association of S1P and S1PR1 with the TGF-β/Smad3 pathway as the potential protective mechanism has remained to be investigated. In the present study, an in vitro ischemia/reperfusion injury model was established and evaluated by analysis of apoptosis, lactate dehydrogenase (LDH) release and caspase3 activity. The mRNA and protein levels of S1PR1, TGF-β and Smad3 after treatment with 1 µM S1P alone or combined with 0.4 µM W146 (a specific S1PR1 antagonist) were assessed. The mRNA expression of five S1PRs (SIPR1-5) and the protein levels of SIPR1 were also assayed following treatment with 1 ng/ml TGF-β for 0, 4 or 24 h. The mRNA expression of SIPR1 and the levels of SIPR1 were further assessed following exposure to 10 µM SB4 (TGFβR1 inhibitor) plus 1 ng/ml TGF-β and 2 µM SIS3 (Smad3 inhibitor) plus 1 ng/ml TGF-β. The results indicated that apoptosis, LDH release and caspase3 activity were all increased in the established IR model. Exogenous S1P increased the mRNA and protein levels of SIPR1, TGF-β and Smad3, which was abolished by addition of W146. Exogenous TGF-β resulted in the stimulation of several SIPRs, most prominently of SIPR1, while supplementation with SB4 and SIS3 offset the stimulation by TGF-β. These results suggested that the TGF-β/Smad3 pathway was closely associated with SIPR1 in the protection of myocardial cells from IR injury.

Correspondence to: Dr Yan Chen, Department of Pediatrics, Jining No. 1 People's Hospital, 6 Jiankang Road, Jining, Shandong 272011, P.R. China
E-mail: zytfang@126.com

Key words: sphingosine 1-phosphate, sphingosine 1-phosphate receptor, ischemia reperfusion, myocardial cells, transforming growth factor-β, Smad3

Introduction

Acute myocardial infarction (AMI) is one of the most common cardiovascular diseases and attributed to occlusion of the epicardial coronary artery, ultimately leading to progressive chronic heart failure. The therapeutic approaches available for AMI injury and myocardial infarction are timely myocardial reperfusion using either thrombolytic therapy or primary percutaneous coronary intervention (1). However, reperfusion to rescue ischemic myocardium may bring a high risk of cardiomyocyte death, namely myocardial ischemia-reperfusion (IR) injury, which includes the following forms: Reperfusion-induced arrhythmias, myocardial stunning, microvascular obstruction and lethal myocardial reperfusion injury (2-7).

Sphingosine 1-phosphate (S1P) is a lysophospholipid mediating a series of cell functions, including cell motility, cell proliferation and differentiation, immune system surveillance, vascular permeability, cytoskeletal organization and viral infections (8). S1P receptors (S1PRs) are a group of G-protein coupled receptors responsible for S1P functions that are referred to as S1PR1-5. However, the five SIPRs differ in their distribution. SIPR1, SIPR2 and SIPR3 are widely expressed, whereas SIPR4 and SIPR5 mainly exist in the immune and nervous systems (9-11). S1P has been reported to have a critical role in the protection of cardiomyocytes and heart function from IR injury in vitro and in vivo (12). For instance, high-density lipoprotein and its lipid component S1P are known to attenuate IR injury (13). S1P has been demonstrated to protect cardiomyocytes of neonatal rats and the heart from ischemic damage in perfused rabbits and mice (14-16). Furthermore, the SIPR1 pathway was reported to induce hypertrophy of cardiomyocytes and reduce mortality of hypoxic cardiomyocytes in vitro (17,18).

TGF-β is a group of structurally associated proteins regulating a number of critical cellular processes, including apoptosis, tumor occurrence and IR (19-21). The biological functions of TGF-β are initiated by binding to two types of transmembrane receptor: TGF-β receptor type I (TGFβR1) and TGFβR2. Activation of TGFβR2 leads to phosphorylation of TGFβR1, which triggers activation of Smad3 and forces Smad3 to translocate into the nucleus (22,23). In a previous study, Vivar et al (24) revealed that TGF-β blocked the IR-induced
apoptosis of cardiac fibroblasts through the Smad3, extracellular signal-regulated kinase (ERK)1/2 and Akt signaling pathways. Furthermore, TGF-β participated in the cross-talk of ERK1/2 and Akt with the Smad2/3 signaling pathway; however, these signaling pathways appear to have independent roles.

Although S1P/S1PR1 and TGF-β3/Smad3 were all demonstrated to be actively implicated in IR injury of myocardial cells, their association has remained to be fully elucidated. The present study reported that exogenous TGF-β significantly increased the levels of S1PR1 compared with those of S1PR2-5. In addition, the results suggested that TGF-β3/Smad3 contributed to the cardioprotective effect of S1P/S1PR1 in an established in vitro IR model.

Materials and methods

Reagents. All treatments were administered at a concentration of 10 nM for 48 h of treatment at 37°C. S1P, WI46, SB-431542 (SB4), SIS3 and TGF-β were all purchased from Sigma-Aldrich (Merck KGaA, Darmstadt, Germany). The primary anti-S1PR1, anti-S1PR2-5 and anti-Smad3 antibodies (Cat. no. ab72806, ab31013, ab40854, respectively) were acquired from Abcam (Cambridge, UK). Fetal bovine serum (FBS) and Dulbecco’s modified Eagle’s medium (DMEM) were purchased from Hyclone (GE Healthcare, Little Chalfont, UK). The secondary antibodies conjugated to horseradish peroxidase (Cat. no. ab6789) were purchased from Zhongshan Goldenbridge Biotech (Beijing, China). The enhanced chemiluminescent (ECL) kit was obtained from Thermo Fisher Scientific (Shanghai, China). For reverse-transcription quantitative polymerase chain reaction (RT-qPCR), the MagExtractor-RNA kit and ReverTra Ace qPCR RT Master Mix with gDNA Remover kit were all from Toyobo (Cat. no. FSQ-301, Tokyo, Japan). The lactate dehydrogenase (LDH) detection kit. The primers, which were synthesized by Sangon Biotech (Shanghai, China), had the following sequences: S1PR1 forward, 5'-AATACCAAGGGCCAGCAAC-3' and reverse, 5'-ACGGGAAATGAGACACTA-3'; S1PR2 forward, 5'-GGCTCTGTCTGTTGATTG-3' and reverse, 5'-GACCTATTTGCTCTC-3'; S1PR3 forward, 5'-AAATTGGCTGGCTTGGGAC-3' and reverse, 5'-CCCCATCGTTGGTGTCT-3'; S1PR4 forward, 5'-ACCATGAGTGCTGGATG-3' and reverse, 5'-CAGATGACTGCTTCTTC-3'; S1PR5 forward, 5'-TGTTGGCTCTACGTCG-3' and reverse, 5'-GGGAAGGTGGCAGTGGTAA-3'; TGF-β forward, 5'-GACCTATCAGCAAGGAGTC-3' and reverse, 5'-GAGAGCACACGCGTTCAG-3'; Smad3 forward, 5'-TGTTGGTGGAGGCTTAG-3' and reverse, 5'-AGCACAGTGAGAGGAGG-3' and reverse, 5'-GACTCTAGACGTCC-3'. RT-qPCR was performed on an ABI7000 fluorescent quantitative PCR system (Applied Biosystems; Thermo Fisher Scientific, Inc.)

Animals. Neonatal mice were purchased from SLRC Laboratory Animal (Changsha, China). Animals were provided with standard rodent chow and water ad libitum. All animal procedures were approved by the Institutional Animal Care and Use Committee of Jining No.1 People's Hospital (Jining, China). All protocols conformed to the National Research Council's Guide for the Care and Use of Laboratory Animals.

Isolation and cultivation of cardiomyocytes. Animals were anesthetized with ether to remove the hearts, which were put in pre-cooled D-hanks medium (Procell, Wuhan, China). The heart tissues were immersed in 0.1% trypsin (Procell) and oscillated overnight at 4°C. Complete medium was added to terminate digestion by incubation at 37°C for 10 min. After discarding the supernatant, the remnant was incubated with 0.08% collagenase for 10 min and the supernatants were pooled. The combined supernatants were centrifuged at 250 x g for 5 min, and DMEM containing 20% FBS was used to re-suspend the precipitates. The cells were then inoculated in a culture dish and incubated for 50 min at 37°C in a humidified atmosphere containing 5% CO2. The non-adherent cells were aspirated to be re-suspended for a second adherence culture. The final concentration of the cells was adjusted to 5x104 cells/ml and 10 ml cell suspension was mixed with 100 µl bromodeoxyuridine to inhibit the proliferation and differentiation of non-fibroblasts but without any obvious effect on the proliferation of the fibroblasts (25). The cells were cultured under the abovementioned conditions and the medium was changed once every 2-3 days. The growth and morphological changes of cardiomyocytes were observed and recorded every day.

In vitro ischemia-reperfusion (IR) model. The IR model was established and evaluated as described previously with minor modifications (26). In brief, the culture medium with 20% FBS was centrifuged at 250 x g for 5 min and resuspended in D-hanks medium with a gas mixture of 95% O2-5% CO2 for 30 min of incubation prior to hypoxia. To simulate ischemia, the culture plate was transferred into an anoxic incubator for 2 h of incubation with a gas mixture of 95% N2-5% CO2. For the reperfusion process, the D-hanks medium was replaced with DMEM containing 20% FBS for 24 h of incubation at 37°C with a gas mixture of 95% O2-5% CO2. The established IR model was evaluated by inspecting apoptosis, LDH release and caspase activity. For the apoptosis assay, cardiomyocytes were collected and centrifuged at 250 x g for 5 min. The cells were inoculated in 6-well flat-bottom plates and digested with 0.3 ml 1X trypsin-EDTA in PBS (37°C). The cells were immediately stained in the dark for 30 min according to the instructions of the Annexin V-FITC/PI apoptosis detection kit (Cat. no. 88-8005-72, Thermo Fisher Scientific, Inc., Waltham, MA, USA). Finally, cellular apoptosis was determined by flow cytometry (FACSCalibur; BD Biosciences, Franklin Lakes, NJ, USA) within 1 h. The measurements of LDH release and caspase-3 activity were performed using respective commercial kits based on the manufacturer's instructions.

Reverse-transcription quantitative polymerase chain reaction (RT-qPCR). Total RNA was extracted from cardiomyocytes treated with 1 µM S1P alone or in combination with 0.4 µM WI46 using a MagExtractor-RNA kit. The extracted total RNA was reverse-transcribed into complementary DNA using ReverTra Ace qPCR RT Master Mix with gDNA Remover kit. The primers, which were synthesized by Sangon Biotech (Shanghai, China), had the following sequences: S1PR1 forward, 5'-AATACCAAGGGCCAGCAAC-3' and reverse, 5'-GCAAGGAAATGAGACACTA-3'; S1PR2 forward, 5'-GGCTCTGTCTGTTGATTG-3' and reverse, 5'-GACCTATTTGCTCTC-3'; S1PR3 forward, 5'-AAATTGGCTGGCTTGGGAC-3' and reverse, 5'-CCCCATCGTTGGTGTCT-3'; S1PR4 forward, 5'-ACCATGAGTGCTGGATG-3' and reverse, 5'-CAGATGACTGCTTCTTC-3'; S1PR5 forward, 5'-TGTTGGCTCTACGTCG-3' and reverse, 5'-GGGAAGGTGGCAGTGGTAA-3'; TGF-β forward, 5'-GACCTATCAGCAAGGAGTC-3' and reverse, 5'-GAGAGCACACGCGTTCAG-3'; Smad3 forward, 5'-TGTTGGTGGAGGCTTAG-3' and reverse, 5'-AGCACAGTGAGAGGAGG-3' and reverse, 5'-GACTCTAGACGTCC-3'. RT-qPCR was performed on an ABI7000 fluorescent quantitative PCR system (Applied Biosystems; Thermo Fisher Scientific, Inc.)
with the following thermocycling procedure: 95°C for 60 sec, followed by 40 cycles of 95°C for 15 sec, 55°C for 15 sec and 72°C for 45 sec. All data were normalized to the housekeeping gene \( \beta \)-actin used as a reference. The relative expression of the target genes was calculated using the \( 2^{-\Delta\Delta Cq} \) method (27).

Western blot analysis. Cardiomyocytes were incubated with 200 ml lysis buffer (25 mM MgCl\(_2\), 5 mM KCl, 20 mM 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid, 0.5% (v/v) complete protease inhibitor and Triton X-100). Protein concentrations were determined using a BCA Protein Quantification kit (Vazyma, Nanjing, China) according to the manufacturer's instructions. Cellular protein (50 mg) was separated using 12% SDS-PAGE prior to transfer onto a polyvinylidene difluoride membrane (EMD Millipore, Billerica, MA, USA). The protein bands were blocked for 1 h in blocking buffer at

---

Figure 1. An *in vitro* ischemia-reperfusion model was established and evaluated in isolated cardiomyocytes. The IR-treated cells were incubated with 1 \( \mu \)M S1P alone and in combination with 0.4 \( \mu \)M W146 for 4 h. (A) Flow cytometric analyses after the staining with Annexin V-FITC and PI. (B) Apoptotic rates obtained by quantification of A (percentage in right upper + and right lower quadrant). (C) LDH release. (D) Caspase-3 activity. *P<0.05; **P<0.01, compared with the control. LDH, lactate dehydrogenase; IR, ischemia-reperfusion; PI, propidium iodide; FITC, fluorescein isothiocyanate; S1P, sphingosine 1-phosphate.
room temperature. Antibodies (monoclonal rabbit anti-S1PR1, TGF-β and Smad3; 1:500 dilution) were incubated with the membranes overnight at 4˚C. Secondary antibodies conjugated to horseradish peroxidase (1:2,000 dilution) were incubated with the membranes for 1 h at room temperature, followed by an ECL assay. The bands were imaged with the ChemiDoc™ XRS Gel image system (Bio-Rad Laboratories, Inc., Hercules, CA, USA) and their intensities were measured using Quantity one v4.62 software (Bio-Rad Laboratories, Inc.).

SIP measurement by liquid chromatography tandem mass spectrometry (LC-MS/MS). The SIP content was measured by LC-MS/MS according to previously described procedures (28).

Statistical analysis. Each experiment was performed in triplicate on three independent occasions. Values are expressed as the mean ± standard deviation and analyzed using one-way analysis of variance with the Least Significant Difference post hoc test. The statistical analyses were performed using SPSS 11.5 software (SPSS, Inc., Chicago, IL, USA). P<0.05 was considered to indicate a statistically significant difference.

Results

Establishment and evaluation of in vitro IR injury model. The isolated myocardial cells were used for the establishment of an in vitro IR injury model. In the established IR model, the apoptotic rate was ~34% (P<0.01 vs. control). Addition of SIP resulted in a further increase of cell apoptosis up to ~39% (P<0.01). However, exogenous W146 inhibited the increase of cell apoptosis caused by SIP, resulting in an apoptotic rate that was significantly different from that of the control (Fig. 1A and B). The LDH levels and caspase-3 activity were also measured due to the stability of LDH in dead cells and the critical role of caspase-3 in apoptosis. The results demonstrated that in IR-treated cells, LDH levels and caspase-3 activity increased by 2.2- and 3.2-fold, respectively (P<0.05), and were further enhanced in IR+SIP-treated cells, resulting in 2.4- and 3.2-fold increases, respectively, compared with the control (P<0.05). However, introduction of W146 inhibited the increases of LDH levels and caspase-3 activity caused by SIP with the resulting values being not significantly different from those in the control group (Fig. IC and D).

SIP increases the mRNA and protein levels of S1PR1, TGF-β and Smad3 in an in vitro IR model. After IR injury, the mRNA and protein levels of S1PR1, TGF-β and Smad3 were significantly increased (P<0.01). Exogenous SIP further increased the mRNA and protein expression of S1PR1, TGF-β and Smad3 (P<0.001). In comparison, W146 abolished the stimulatory effects of SIP on S1PR1, TGF-β and Smad3 mRNA and protein expression, resulting in levels that were comparable to those of the control group (Fig. 2).

TGF-β/Smad3 pathway activation stimulates SIP/S1PR1 in IR injury model. Induction of IR resulted in upregulation of S1PR1-3 in myocardial cells (P<0.05 or P<0.01). Pretreatment with TGF-β caused a significant increase of S1PR1 mRNA at 4 h (P<0.05). After 24 h of treatment with TGF-β, the levels of S1PR1-3 mRNA were all significantly stimulated (P<0.05 or P<0.01). The expression of S1PR5 mRNA was not detectable, while S1PR4 mRNA appeared to not be significantly affected by TGF-β (Fig. 3A). The protein levels of S1PR1 were also increased by pretreatment with TGF-β for 0, 4 and 24 h (P<0.05 or P<0.01; Fig. 3B). These results suggested that S1PR1 mRNA was more affected by TGF-β than S1PR2 and S1PR3 mRNA. By using TGFβR1 inhibitor SB4 and Smad3 inhibitor SIS3, the stimulatory effects of TGF-β on S1PR1 and SIP were abolished (Fig. 4A and B).

Discussion

In the present study, an in vitro IR model was successfully established in myocardial cells and evaluated by analysis of apoptosis, LDH release and caspase-3 activity. It was observed that extraneous TGF-β induced the most significant increase of S1PR1 among the five SIP receptors (S1PR1-5) within 24 h. External SIP caused elevated S1PR1, TGF-β and Smad3, while W146, a specific S1PR1 antagonist (29), abolished the effects of SIP. It was also revealed that SB4 (TGFβR1 inhibitor) and SIS3 (Smad3 inhibitor) offset the stimulatory effect of TGF-β on the levels of SIP and S1PR1. These results suggested an intimate association of SIP/S1PR1 with TGF-β/Smad3.
As mentioned above, the levels of S1P rose following IR, which was indicative of the protection of myocardial cells from IR (14-16). The inherent TGF-β levels increased when IR occurred and autoinduction or exogenous addition of TGF-β also protected the heart from IR to a large extent, suggesting a potentially cardioprotective role of TGF-β against IR in cardiomyocytes (30-33). The results of the present study were consistent with those of these previous studies on IR. The present study also observed that replenishment of S1P further promoted the mRNA and protein expression of S1PR1, TGF-β and Smad3 after IR. These results did not only suggest a protective effect of S1P against IR, but also the close association of S1P/S1PR1 with TGF-β/Smad3. The present results also demonstrated that the increases of S1PR1, TGF-β and Smad3 were almost reversed by the addition of the S1PR1 antagonist W146, which was consistent with a previous study (34). From these results, it may be deduced that the abolishment of the protective effect caused by W146 was mainly due to the disruption of the ligation between S1P and S1PR1, resulting in the interruption of the association of S1P/S1PR1 with TGF-β/Smad3.

As is known, differential expression patterns of S1PR subtypes are important for subsequent cellular responses (35). Although S1PR1-5 are widely distributed in numerous tissue types, the present results indicated that the expression of S1PR1-3 mRNA was significantly upregulated after induction of IR, while the expression of S1PR4 and 5 was generally low and not affected, suggesting that S1PR1-3 may have a more important role in cardioprotection than S1PR4 and -5. However, the relative expression of S1PR1-3 in cardiac myocytes is still under debate. For instance, Forrest et al (36) reported that S1PR1 was not detected in myocytes in adult rat and mouse heart sections with subtype-selective antibodies against S1PRI.
and S1PR3 mRNA are expressed in myocardial cells, their roles in TGF-β-mediated cardioprotection via S1P/S1PR1 were also investigated in the present study. It was revealed that extraneous TGF-β increased the levels of S1PR1 mRNA but not those of S1PR2 and S1PR3 mRNA after 4 h of incubation. The results also suggested that the stimulatory effect of TGF-β on the expression of S1PR1 mRNA was more prominent than on that of S1PR2 and S1PR3 mRNA, implying a more critical role of S1PR1 in the treatment of IR. The wide-spectrum use of inhibitors vastly facilitates the study of TGF-β-mediated cardioprotective effect of S1P/S1PR1 by TGF-β.

In conclusion, the present study suggested that the TGF-β/Smad3 pathway mediates the protection of myocardial cells from IR injury via the stimulation of S1P/SIPR1. However, the TGF-β pathway may be either Smad-dependent or –independent (43), and the mRNA levels of S1PR2 and S1PR3 were also significantly affected by TGF-β. Further study is required to elucidate the underlying cardioprotective mechanisms for IR treatment and the association of S1P/SIPRs with TGF-β-mediated pathways.

References

1. Hausenloy DJ and Yellon DM: Myocardial ischemia-reperfusion injury: A neglected therapeutic target. J Clin Invest 123: 92-100, 2013.
2. Braunwald E and Kloner RA: Myocardial reperfusion: A double-edged sword? J Clin Invest 76: 1713-1719, 1985.
3. Piper HM, Garcia-Dorado D and Ovize M: A fresh look at reperfusion injury. Cardiovasc Res 38: 291-300, 1998.
4. Yellon DM and Hausenloy DJ: Myocardial reperfusion injury. N Engl J Med 357: 1121-1135, 2007.
5. Heasee and Tosaki A: Free radicals and reperfusion-induced arrhythmias: Protection by spin trap agent PBN in the rat heart. Circ Res 60: 375-383, 1987.
6. Kloner RA, Bolli R, Marban E, Reinhil P and Braunwald E: Medical and cellular implications of stunning, hibernation, and preconditioning: An NHLBI workshop. Circulation 97: 1848-1867, 1998.
7. Krug A, Du Mesnil de Rochemont and Korb G: Blood supply of the myocardium after temporary coronary occlusion. Circ Res 19: 57-62, 1966.
8. Rosen H, Germana Sanna M, Gonzalez-Cabrera PJ and Roberts E: The organization of the sphingosine 1-phosphate signaling system. Curr Top Microbiol Immunol 378: 1-21, 2014.
9. Ishii I, Fukushima N, Ye X and Chun J: Lysophospholipid receptors: Signaling and biology. Annu Rev Biochem 73: 321-354, 2004.
10. Herr DS, Heise CE, Ancellin N, O'Dowd BF, Shi GJ, Heavens RP, Rigby MR, Hia T, Mandala S, McAllister G, et al: Characterization of a novel sphingosine 1-phosphate receptor, Edg-8. J Biol Chem 275: 14281-14286, 2000.
11. Gräler MH, Grosse R, Kusch A, Kremmer E, Gudermann T and Lipp M: The sphingosine 1-phosphate receptor SIP4 regulates cell shape and motility via coupling to G1 and G12/13. J Cell Biochem 89: 507-519, 2003.
12. Krupp M: Cardioprotective role of sphingosine-1-phosphate. J Physiol Pharmacol 62: 601-607, 2001.
13. Theilmeier G, Schmidt C, Herrmann J, Keul P, Schäfers M, Herrgott I, Mersmann J, Larmann J, Herrmann S, Stypmann J, et al: High-density lipoproteins and their constituent, sphingosine-1-phosphate, directly protect the heart against ischemia/reperfusion injury in vivo via the SIP3 lysosphospholipid receptor. Circulation 114: 1403-1409, 2006.
14. Jin ZQ, Goetzl EJ and Karliner JS: Sphingosine kinase activation mediates ischemic preconditioning in murine heart. Circulation 110: 1980-1986, 2004.
15. Jin ZQ, Zhou HZ, Zhu P, Honbo N, Mochly-Rosen D, Messing RO, Goetzl EJ, Karliner JS and Gray MO: Cardioprotection mediated by sphingosine-1-phosphate and ganglioside GM-1 in wild-type and PKC epsilon knockout mouse hearts. Am J Physiol Heart Circ Physiol 282: H1970-H1977, 2002.
16. Karliner JS, Honbo N, Summers K, Gray MO and Goetzl EJ: The lysophospholipids sphingosine-1-phosphate and lyposphathatic acid enhance survival during hypoxia in neonatal rat cardiac myocytes. J Mol Cell Cardiol 33: 1713-1717, 2001.
17. Robert P, Tsui P, Laville MP, Livi GP, Sarau HM, Bril A and Berrebi-Bertrand I: EDG1 receptor stimulation leads to cardiac hypertrophy in rat neonatal myocytes. J Mol Cell Cardiol 33: 1589-1606, 2001.
18. Zhang J, Honbo N, Goetzl EJ, Chatterjee K, Karliner JS and Gray MO: Signals from type 1 sphingosine-1-phosphate receptors enhance adult mouse cardiac myocyte survival during hypoxia. Am J Physiol Heart Circ Physiol 293: H3150-H3158, 2007.
19. Toledo-Pereyra LH, Toledo AH, Walsh J and Lopez-Nebli F: Molecular signaling pathways in ischemia/reperfusion. Exp Clin Transplant 2: 174-177, 2004.
20. Truty MJ and Urrutia R: Basics of TGF-beta and pancreatic cancer. Pancreatology 7: 423-435, 2007.
21. Chen H, Li D, Saldeen T and Mehta JL: TGF-β1 attenuates myocardial ischemia-reperfusion injury via inhibition of upregulation of MMP-1. Am J Physiol Heart Circ Physiol 284: H616-H617, 2003.
22. Feng XH and Derynck R: Specificity and versatility in TGF-β signaling through Smads. Annu Rev Biochem 72: 659-693, 2005.
23. Massague J, Seoane J and Wotton D: Smad transcription factors. Genes Dev 19: 2783-2810, 2005.
24. Vivar R, Humerez C, Ayala P, Olmedo I, Catalán M, García L, Lavandero S and Díaz-Araya G: TGF-β1 prevents simulated ischemia/reperfusion-induced cardiac fibroblast apoptosis by activation of both canonical and non-canonical signaling pathways. Biochim Biophys Acta 1832: 754-762, 2013.
25. Rutter WJ, Pictet RL and Morris PW: Toward molecular mechanisms of developmental processes. Annu Rev Biochem 72: 601-646, 1973.
26. Chen Z, Qi Y and Gao C: Cardiac myocyte-protective effect of microRNA-22 during ischemia and reperfusion through disrupting the caveolin-3/eNOS signaling. Int J Clin Exp Pathol 8: 4614-4626, 2015.
27. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−ΔΔC(T)) method. Methods 25: 402‑408, 2001.
28. Zhao J, Liu J, Lee JF, Zhang W, Kandouz M, VanHecke GC, Chen S, Ahn YH, Lonardo FanLeed J, TGF-β3/Smad3 pathwysmulates Sphingosine-1-phosphate receptor 3 Expression: IMPLICATION OF SPHINGOSINE-1 PHOSPHATE RECEPTOR 3 IN LUNG ADENOCARCINOMA PROGRESSION. J Biol Chem 291: 27343-27353, 2016.
29. Ham A, Kim M, Kim JY, Brown KM, Fruttiger M, D'Agati VD and Lee HT: Selective deletion of the endothelial sphingosine-1-phosphate receptor 1 receptor exacerbates kidney ischemia-reperfusion injury. Kidney Int 85: 807‑823, 2014.
30. Lefer AM, Ma XL, Weyrich AS and Scalia R: Mechanism of the cardioprotective effect of transforming growth factor beta 1 in feline myocardial ischemia and reperfusion. Proc Natl Acad Sci USA 100: 1018-1022, 2003.
31. Lefer AM, Tsao P, Aoki N and Palladino MA Jr: Mediation of cardioprotection by transforming growth factor-beta. Science 249: 61-64, 1990.
32. Mehta JL, Yang BC, Strates BS and Mehta P: Role of TGF-beta1 in platelet-mediated cardioprotection during ischemia-reperfusion in isolated rat hearts. Growth Factors 16: 179-190, 1999.

33. Moses HL, Yang EY and Pietenpol JA: TGF-β stimulation and inhibition of cell proliferation: New mechanistic insights. Cell 63: 245-247, 1990.

34. Tsukada YT, Sanna MG, Rosen H and Gottlieb RA: S1P-selective agonist SEW2871 exacerbates reperfusion arrhythmias. J Cardiovasc Pharmacol 50: 660-669, 2007.

35. Means CK and Brown JH: Sphingosine-1-phosphate receptor signalling in the heart. Cardiovasc Res 82: 193-200, 2009.

36. Forrest M, Sun SY, Hajdu R, Bergstrom J, Card D, Doherty G, Hale J, Keohane C, Meyers C, Milligan J, et al: Immune cell regulation and cardiovascular effects of sphingosine 1-phosphate receptor agonists in rodents are mediated via distinct receptor subtypes. J Pharmacol Exp Ther 309: 758-768, 2004.

37. Mazurais D, Robert P, Gout B, Berrebi-Bertrand I, Laville MP and Calmels T: Cell type-specific localization of human cardiac S1P receptors. J Histochem Cytochem 50: 661-670, 2002.

38. Liu Y, Wada R, Yamashita T, Mi Y, Deng CX, Hobson JP, Rosenfeldt HM, Nava VE, Chae SS, Lee MJ, et al: Edg-1, the G protein-coupled receptor for sphingosine-1-phosphate, is essential for vascular maturation. J Clin Invest 106: 951-961, 2000.

39. Nakajima N, Cavalli AL, Biral D, Glembotski CC, McDonough PM, Ho PD, Betto R, Sandona D, Palade PT, Dettbarn CA, et al: Expression and characterization of Edg-1 receptors in rat cardiomyocytes: Calcium deregulation in response to sphingosine 1-phosphate. Eur J Biochem 267: 5679-5686, 2000.

40. Zhang G, Contos JJ, Weiner JA, Fukushima N and Chun J: Comparative analysis of three murine G-protein coupled receptors activated by sphingosine-1-phosphate. Gene 227: 89-99, 1999.

41. Liu R, Das B, Xiao W, Li Z, Li H, Lee K and He JC: A Novel Inhibitor of Homeodomain Interacting protein Kinase 2 mitigates kidney fibrosis through inhibition of the TGF-β1/Smad3 pathway. J Am Soc Nephrol 28: 2133-2143, 2017.

42. Yan YM, Ai J, Shi YN, Zuo ZL, Hou B, Luo J and Cheng YX: (+/-)-Aspongamide A, an N-acetyldopamine trimer isolated from the insect Aspongopus chinensis, is an inhibitor of p-Smad3. Org Lett 16: 532-535, 2014.

43. Kiyono K, Suzuki HI, Matsuyma H, Morishita Y, Komuro A, Kano MR, Sugimoto K and Miyazono K: Autophagy is activated by TGF-β and potentiates TGF-β-mediated growth inhibition in human hepatocellular carcinoma cells. Cancer Res 69: 8844-8852, 2009.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.